Basilea Pharmaceutica AG Announces Commercial Availability of Zevtera in the United States

Allschwil, Switzerland, May 20, 2025 — Basilea Pharmaceutica AG, a biopharmaceutical company listed on the SIX Swiss Exchange (Ticker: BSLN), has announced the commercial availability of its antibiotic Zevtera® (ceftobiprole medocaril for injection) in the United States. This development marks a significant milestone for Basilea, which focuses on addressing severe bacterial and fungal infections.

Zevtera is now available through Basilea’s partner, Innoviva Specialty Therapeutics, Inc., a wholly owned subsidiary of Innoviva, Inc. (NASDAQ: INVA). The antibiotic is primarily used in hospital settings to treat bacterial infections, including those caused by Staphylococcus aureus bacteria, such as methicillin-resistant strains (MRSA).

Key Details:

  • Product: Zevtera® (ceftobiprole medocaril for injection)
  • Use: Treatment of bacterial infections, including MRSA
  • Availability: Commercially available in the United States
  • Partner: Innoviva Specialty Therapeutics, Inc.

Company Overview:

Basilea Pharmaceutica AG operates in the health care sector, specifically within the biotechnology industry. The company is committed to developing treatments for resistant and non-responsive fungal, bacterial, and cancer infections. As of May 18, 2025, Basilea’s close price was CHF 44.5, with a market capitalization of CHF 580,980,000. The company’s price-to-earnings ratio stands at 7.8.

Market Context:

The introduction of Zevtera in the U.S. market is expected to enhance Basilea’s portfolio of commercial-stage products. The antibiotic addresses a critical need for effective treatments against severe bacterial infections, such as Staphylococcus aureus bacteremia (SAB), which is associated with significant morbidity and mortality. With a 30-day all-cause mortality rate of around 20%, there is a high demand for improved therapies for such infections.

Conclusion:

The commercial availability of Zevtera in the United States represents a strategic expansion for Basilea Pharmaceutica AG, potentially strengthening its position in the biopharmaceutical market. The company’s focus on severe infections aligns with the growing need for advanced therapeutic solutions in healthcare settings.